Phase III Study of AK160 in Patients With Dupuytren's Contracture

Trial Profile

Phase III Study of AK160 in Patients With Dupuytren's Contracture

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Dupuytren's contracture
  • Focus Registrational; Therapeutic Use
  • Acronyms CORD-J
  • Sponsors Asahi Kasei
  • Most Recent Events

    • 03 Jul 2015 Asahi Kasei Pharma Corporation has received approval for manufacture and sale of collagenase clostridium histolyticum [XIAFLEX] for the treatment of Dupuytren's contracture in Japan, according to media release.
    • 31 Jul 2014 Asahi Kasei Pharma Corporation has completed a regulatory submission for XIAFLEX for Dupuytren's contracture in Japan, and a PMDA review is expteced to be completed by mid 2015, according to an Auxilium Pharmaceuticals media release.
    • 30 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top